Scientific Resources mWTX-330, an IL 12 INDUKINE Molecule, Activates and Reshapes Tumor-infiltrating… A multicenter phase 1/1b dose escalation study of WTX-124 as a monotherapy and in combination with pembrolizumab in patients with selected advanced or metastatic solid tumors (Poster presented at AACR 2023) 1.4 MB A first-in-human, phase 1, multicenter dose escalation and dose expansion study of WTX-330 in adult patients with advanced or metastatic solid tumors or non-Hodgkin lymphoma (Poster presented at AACR 2023) 1.5 MB Generation of IL-21 INDUKINETM Molecules for the Treatment of Cancer (Poster presentated at AACR 2023) 1.1 MB mWTX-330, an IL-12 INDUKINE™ Molecule, Selectively Activates Tumor Infiltrating Lymphocytes & Reprograms the TME in Murine Syngeneic Tumor Models (Poster presented at SITC 2022, Abstract 1096) 1.7 MB WTX-124 is a Novel IL-2 Prodrug that is Conditionally Activated in Tumors and Drives Anti-Tumor Immunity by Activating Tumor Infiltrating CD8+ T Cells (Poster presented at AACR 2022) 1.3 MB WTX-330 is a Conditionally Activated IL-12 Prodrug that Fundamentally Reprograms Tumor Infiltrating CD8+ T Cells and Drives Tumor Regression (Poster presented at AACR 2022) 1.6 MB Discovery of a Conditionally Activated Interleukin-2 that Promotes Anti-tumor Immunity and Induces Tumor Regression (Article published in Cancer Immunology Research, a journal of AACR, March 2022) 5 MB Conditionally Activated IL-12 or IFNα INDUKINETM Molecules Inhibit Syngeneic Lymphoma Tumor Growth in Mice, Induce Anti-Tumor Immune Responses and Are Tolerated in Non-human Primates (Presented at ASH 2021) 3.5 MB WTX-124 is a novel IL-2 pro-drug that is conditionally activated in tumors and drives anti-tumor immunity in murine syngeneic cancer models (Presented as a poster at SITC 2021 Annual Mtg) 1.6 MB Current page 1 Page 2 Next page › Last page »
A multicenter phase 1/1b dose escalation study of WTX-124 as a monotherapy and in combination with pembrolizumab in patients with selected advanced or metastatic solid tumors (Poster presented at AACR 2023) 1.4 MB
A first-in-human, phase 1, multicenter dose escalation and dose expansion study of WTX-330 in adult patients with advanced or metastatic solid tumors or non-Hodgkin lymphoma (Poster presented at AACR 2023) 1.5 MB
Generation of IL-21 INDUKINETM Molecules for the Treatment of Cancer (Poster presentated at AACR 2023) 1.1 MB
mWTX-330, an IL-12 INDUKINE™ Molecule, Selectively Activates Tumor Infiltrating Lymphocytes & Reprograms the TME in Murine Syngeneic Tumor Models (Poster presented at SITC 2022, Abstract 1096) 1.7 MB
WTX-124 is a Novel IL-2 Prodrug that is Conditionally Activated in Tumors and Drives Anti-Tumor Immunity by Activating Tumor Infiltrating CD8+ T Cells (Poster presented at AACR 2022) 1.3 MB
WTX-330 is a Conditionally Activated IL-12 Prodrug that Fundamentally Reprograms Tumor Infiltrating CD8+ T Cells and Drives Tumor Regression (Poster presented at AACR 2022) 1.6 MB
Discovery of a Conditionally Activated Interleukin-2 that Promotes Anti-tumor Immunity and Induces Tumor Regression (Article published in Cancer Immunology Research, a journal of AACR, March 2022) 5 MB
Conditionally Activated IL-12 or IFNα INDUKINETM Molecules Inhibit Syngeneic Lymphoma Tumor Growth in Mice, Induce Anti-Tumor Immune Responses and Are Tolerated in Non-human Primates (Presented at ASH 2021) 3.5 MB
WTX-124 is a novel IL-2 pro-drug that is conditionally activated in tumors and drives anti-tumor immunity in murine syngeneic cancer models (Presented as a poster at SITC 2021 Annual Mtg) 1.6 MB
